Retinitis Pigmentosa: Evaluation and Management
All patients with suspected retinitis pigmentosa require comprehensive ophthalmologic evaluation including visual acuity, visual field testing, electroretinography (ERG), and genetic testing, followed by management of associated complications (particularly cystoid macular edema and cataracts), low vision rehabilitation, and genetic counseling 1, 2, 3, 4, 5.
Initial Diagnostic Evaluation
Essential Clinical Assessment
The diagnostic workup must include:
- Visual acuity testing - Document baseline and monitor progression
- Visual field testing - Identifies characteristic peripheral constriction progressing centrally
- Fundus examination - Look for bone spicule pigmentation, attenuated retinal vessels, and waxy optic disc pallor 4
- Electroretinography (ERG) - The gold standard for diagnosis; shows reduced or absent rod and cone responses 3, 4
- Optical coherence tomography (OCT) - Assesses macular structure and detects cystoid macular edema
- Genetic testing - Critical for confirming diagnosis, genetic counseling, and identifying candidates for emerging gene-specific therapies 2, 3, 5, 6
Key History Elements
Focus on:
- Age of symptom onset (night blindness typically first)
- Rate of progression
- Family history and inheritance pattern
- Systemic associations (hearing loss suggesting Usher syndrome, obesity/polydactyly suggesting Bardet-Biedl syndrome) 3, 4
Management Strategy
1. Treatment of Associated Complications
Cystoid macular edema (CME) is the most important treatable complication:
- Carbonic anhydrase inhibitors (oral or topical) are first-line treatment 7, 5
- Monitor with OCT at regular intervals
- Treatment can preserve central vision even when peripheral vision is lost
Cataract surgery when visually significant:
- RP patients commonly develop posterior subcapsular cataracts
- Surgery can improve quality of life when cataracts contribute to vision loss 5
2. Nutritional Supplementation
The evidence for nutritional therapy is limited:
- Vitamin A palmitate (15,000 IU daily) showed modest benefit in slowing ERG decline in some studies, but evidence quality is low 5, 8
- Docosahexaenoic acid (DHA) and lutein showed some ERG changes in phase III trials but no clinically significant visual acuity improvement 8
- Do not recommend routine supplementation based on current evidence, as no therapy has demonstrated clinically meaningful visual acuity preservation 8
3. Low Vision Rehabilitation
Mandatory referral to low vision services for all patients with functional impairment 9, 2, 5:
- Optical aids (magnifiers, telescopes)
- Electronic assistive devices (smartphone applications, smart speakers)
- Orientation and mobility training
- Occupational therapy for activities of daily living
- Psychological support and peer support groups 9
4. Genetic Counseling
All patients require genetic counseling 2, 5:
- Discuss inheritance patterns and recurrence risks
- Inform about reproductive options
- Identify family members who may benefit from screening
- Discuss emerging gene-specific therapies
5. Emerging Therapies (Limited Availability)
Argus II Retinal Prosthesis - FDA-approved for advanced RP with bare light perception or worse 1, 9:
- Requires careful patient selection and expectation counseling
- Provides basic visual function (motion detection, object localization)
- Note: No longer commercially available as of recent years 9
Gene therapy - Currently available only for specific mutations (e.g., RPE65-associated disease, which is technically Leber congenital amaurosis) 2, 3, 5:
- Genetic testing essential to identify candidates
- Multiple gene-specific therapies in clinical trials
Follow-up Schedule
Annual comprehensive examinations including:
- Visual acuity and visual fields
- Fundus examination and OCT
- Assessment for CME and cataracts
- Functional status and rehabilitation needs 10, 2
More frequent monitoring if:
- CME develops (every 3-6 months)
- Rapid progression documented
- New symptoms emerge
Critical Pitfalls to Avoid
Delaying genetic testing - This is essential for diagnosis confirmation, counseling, and identifying candidates for emerging therapies 2, 6
Missing treatable CME - Regular OCT monitoring is mandatory as CME treatment can preserve central vision 5
Failing to refer for low vision services early - Rehabilitation is most effective when initiated before severe vision loss 9, 2
Overlooking systemic associations - Screen for Usher syndrome (hearing loss), Bardet-Biedl syndrome, and other syndromic forms 3
Providing false hope about nutritional supplements - Current evidence does not support meaningful visual benefit from vitamin A or other supplements 8
Communication with Patients
Be direct about prognosis while emphasizing:
- Many patients maintain functional vision for decades
- Central vision often preserved until late stages
- Rehabilitation can maintain independence and quality of life
- Gene-specific therapies are rapidly advancing
- Depression is treatable and should not be ignored 9